Latest & greatest articles for colon cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colon cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colon cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colon cancer screening

161. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. (Abstract)

of distal colorectal cancer (rectum and sigmoid colon) was reduced by 50% (0.50, 0.42-0.59; secondary outcome). The numbers needed to be screened to prevent one colorectal cancer diagnosis or death, by the end of the study period, were 191 (95% CI 145-277) and 489 (343-852), respectively.Flexible sigmoidoscopy is a safe and practical test and, when offered only once between ages 55 and 64 years, confers a substantial and longlasting benefit.Medical Research Council, National Health Service R&D, Cancer (...) Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Colorectal cancer is the third most common cancer worldwide and has a high mortality rate. We tested the hypothesis that only one flexible sigmoidoscopy screening between 55 and 64 years of age can substantially reduce colorectal cancer incidence and mortality.This randomised controlled trial was undertaken in 14 UK centres. 170 432 eligible men and women, who had indicated

2010 Lancet Controlled trial quality: predicted high

162. Flexible sigmoidoscopy for colorectal cancer screening

Flexible sigmoidoscopy for colorectal cancer screening Flexible sigmoidoscopy for colorectal cancer screening Flexible sigmoidoscopy for colorectal cancer screening Ellery B, Mundy L, Hiller JE Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ellery B, Mundy L, Hiller JE. Flexible sigmoidoscopy for colorectal cancer screening. Adelaide (...) are currently in the process of revising the Australian guidelines for the detection of colorectal cancer and therefore HealthPACT have recommended that this document be considered as part of this ongoing process. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Colorectal Neoplasmss; Mass Screening; Sigmoidoscopy Language Published English Country of organisation Australia English summary An English language summary is available. Address for correspondence Adelaide Health

2010 Health Technology Assessment (HTA) Database.

163. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test Full Text available with Trip Pro

Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test Lejeune C, Dancourt V, Arveux P, Bonithon-Kopp C, Faivre J Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of two-yearly colorectal cancer screening, using a guaiac faecal occult blood test (FOBT) or an immunochemical FOBT, in the general population, compared with no screening. The authors concluded that screening with immunochemical FOBT

2010 NHS Economic Evaluation Database.

164. Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60-69 years

MH, Toledano AY, et al. Accuracy of CT colonography for detection of large adenomas and cancers. New England Journal of Medicine 2008; 239(2): 457-463. Tappenden P, Eggington S, Nixon R, et al. Colorectal cancer screening options appraisal: cost-effectiveness, cost-utility and resource impact of alternative screening options for colorectal cancer. Sheffield: University of Sheffield, School of Health and Related Research. Report to the English Bowel Cancer Screening Working Group. 2004. Ness RM (...) , Holmes AM, Klein R, et al. Utility valuations for outcome states of colorectal cancer. American Journal of Gastroenterology 1999; 94(6): 1650-1657. Indexing Status Subject indexing assigned by NLM MeSH Aged; Colonography, Computed Tomographic /economics; Colorectal Neoplasms /economics /prevention & Cost-Benefit Analysis; Female; Great Britain; Humans; Male; Markov Chains; Mass Screening /economics; Middle Aged; Occult Blood; Quality-Adjusted Life Years; Sensitivity and Specificity; State Medicine

2010 NHS Economic Evaluation Database.

165. Tailoring Colon Cancer Screening

their first follow-up colonoscopy in 3 years. Patients who have had numerous adenomas, a malignant adenoma (with invasive cancer), a large sessile adenoma, or an incomplete colonoscopy should have a short interval follow-up colonoscopy based on clinical judgment. The rationale behind these guidelines from the GI Consortium Panel lies in evidence that colonoscopic polypectomy and surveillance reduces subsequent colorectal cancer incidence. 2,3 A post-polypectomy surveillance study by Citarda et. al showed (...) Tailoring Colon Cancer Screening Tailoring Colon Cancer Screening – Clinical Correlations Search Tailoring Colon Cancer Screening December 11, 2009 3 min read Guidelines for Colorectal Cancer Screening and the Recent Evidence Behind Them Nazia Hasan, MD MPH Faculty peer reviewed For most residents, screening for colorectal cancer (CRC) may seem as established as that for breast and cervical cancer. In reality, the use of CRC screening has only recently approached that of screening for those

2009 Clinical Correlations

166. Using CT colonography as a triage technique after a positive faecal occult blood test in colorectal cancer screening Full Text available with Trip Pro

Using CT colonography as a triage technique after a positive faecal occult blood test in colorectal cancer screening The purpose of this study was to evaluate the effectiveness of CT colonography (CTC) as a triage technique in faecal occult blood test (FOBT)-positive screening participants.Consecutive guaiac (G-FOBT) and immunochemical (I-FOBT) FOBT-positive patients scheduled for colonoscopy underwent CTC with iodine tagging bowel preparation. Each CTC was read independently by two experienced (...) observers. Per patient sensitivity, specificity and positive and negative predictive values (PPV and NPV) were calculated based on double reading with different CTC cut-off lesion sizes using segmental unblinded colonoscopy as the reference standard. The acceptability of the technique to patients was evaluated with questionnaires.302 FOBT-positive patients were included (54 G-FOBT and 248 I-FOBT). 22 FOBT-positive patients (7%) had a colorectal carcinoma and 211 (70%) had a lesion >or=6 mm. Participants

2009 EvidenceUpdates

167. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.

Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants

2009 American Cancer Society

168. Colorectal cancer screening clinical practice guideline.

Colorectal cancer screening clinical practice guideline. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline

2009 Kaiser Permanente Care Management Institute

169. Tailoring Colon Cancer Screening

tests. This blog series aims to review the updated guidelines for CRC screening illustrated through cases. CASE 1: A 46 year old African-American male presents for routine health maintenance. He has never had any colorectal cancer screening, denies a personal or family history of GI disorders including malignancy, and is currently asymptomatic. What modality is the most preferred by the ACG for CRC screening in this patient? a. Flexible Sigmoidoscopy b. Fecal immunochemical test for blood (FIT) c (...) Tailoring Colon Cancer Screening Tailoring Colon Cancer Screening – Clinical Correlations Search Tailoring Colon Cancer Screening October 29, 2009 5 min read Guidelines for Colorectal Cancer Screening and the Recent Evidence Behind Them Nazia Hasan, MD MPH Faculty peer reviewed For most residents, screening for colorectal cancer (CRC) may seem as established as that for breast and cervical cancer. In reality, the use of CRC screening has only recently approached that of screening for those

2009 Clinical Correlations

170. CT Colonography-The Future of Colorectal Cancer Screening?

and would like to know how it compares to conventional colonoscopy. Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer death in the United States(1). Multiple studies have demonstrated that most colorectal cancers develop from smaller adenomas(2). These adenomas, or polyps, are presymptomatic lesions that can be identified and removed before malignant transformation occurs. Current CRC screening techniques, which include fecal occult blood testing (...) , facilitating differentiation from polyps and thereby potentially obviating the need for colon prep before CTC. Because most patients find the colon prep the most onerous part of the experience, such prepless CT could lead to significantly more people being screened. Research is also being devoted to computer-assisted efforts to enhance polyp visualization. Software programs have been designed to detect colorectal lesions with morphologies suggestive of polyps(8). Such programs will no doubt increase

2009 Clinical Correlations

171. Impact of age and comorbidity on colorectal cancer screening among older veterans. Full Text available with Trip Pro

Impact of age and comorbidity on colorectal cancer screening among older veterans. The Veterans Health Administration, the American Cancer Society, and the American Geriatrics Society recommend colorectal cancer screening for older adults unless they are unlikely to live 5 years or have significant comorbidity that would preclude treatment.To determine whether colorectal cancer screening is targeted to healthy older patients and is avoided in older patients with severe comorbidity who have life (...) to persons who do not use the VA system is uncertain.Advancing age was inversely associated with colorectal cancer screening, whereas comorbidity was a weaker predictor. More attention to comorbidity is needed to better target screening to older patients with substantial life expectancies and avoid screening older patients with limited life expectancies. primary funding source: VA Health Services Research and Development.

2009 Annals of Internal Medicine

172. Patient and physician reminders to promote colorectal cancer screening: a randomized controlled trial Full Text available with Trip Pro

Patient and physician reminders to promote colorectal cancer screening: a randomized controlled trial Screening reduces colorectal cancer mortality, but effective screening tests remain underused. Systematic reminders to patients and physicians could increase screening ratesWe conducted a randomized controlled trial of patient and physician reminders in 11 ambulatory health care centers. Participants included 21 860 patients aged 50 to 80 years who were overdue for colorectal cancer screening (...) among patients with 3 or more primary care visits (59.5% vs 52.7%; P = .07). Detection of adenomas tended to increase with patient mailings (5.7% vs 5.2%; P = .10) and physician reminders (6.0% vs 4.9%; P = .09).Mailed reminders to patients are an effective tool to promote colorectal cancer screening, and electronic reminders to physicians may increase screening among adults who have more frequent primary care visits.

2009 EvidenceUpdates Controlled trial quality: predicted high

173. Review: faecal occult blood test screening reduces risk of colorectal cancer mortality

Review: faecal occult blood test screening reduces risk of colorectal cancer mortality Review: faecal occult blood test screening reduces risk of colorectal cancer mortality | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: faecal occult blood test screening reduces risk of colorectal cancer mortality Article Text Therapeutics Review: faecal occult blood test screening reduces risk of colorectal cancer mortality Statistics from

2009 Evidence-Based Medicine

174. Once-only flexible sigmoidoscopy screening for colorectal cancer may not reduce colorectal cancer incidence or mortality

in a national population registry. People who died or had colorectal cancer before the study entry date were excluded, and those allocated to screening were included in the analysis but were not screened if they had prior open colorectal surgery, severe chronic cardiac or pulmonary disease, need for long-term care, cerebrovascular accident or hospital admission for coronary events in the past 3 months, were currently receiving lifelong anticoagulant therapy or cytotoxic therapy or radiotherapy (...) Once-only flexible sigmoidoscopy screening for colorectal cancer may not reduce colorectal cancer incidence or mortality Once-only flexible sigmoidoscopy screening for colorectal cancer may not reduce colorectal cancer incidence or mortality | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using

2009 Evidence-Based Medicine

175. Cost-effectiveness of CT colonography to screen for colorectal cancer

Cost-effectiveness of CT colonography to screen for colorectal cancer Cost-effectiveness of CT colonography to screen for colorectal cancer Cost-effectiveness of CT colonography to screen for colorectal cancer Zauber AG, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Savarino JE, van Ballegooijen M, Kuntz KM Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Zauber AG, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Savarino JE, van Ballegooijen M, Kuntz KM. Cost-effectiveness of CT colonography to screen for colorectal cancer. Rockville: Agency for Healthcare Research and Quality (AHRQ). Technology Assessment. 2009 Authors' objectives Despite recent declines in both incidence and mortality, colorectal cancer (CRC) is the second most common cause of cancer death in the United States. CRC screening has been shown to reduce CRC mortality by 15

2009 Health Technology Assessment (HTA) Database.

176. CT colonography (virtual colonoscopy) for colon cancer screening

included comments from the principal investigator of the trial citing the importance of adequate training and credentialing of CT colonography readers for the effectiveness of the technique. This suggests the need to credential providers who perform this procedure, at least in the initial phase of dissemination. The 2008 guideline on colon cancer screening, a joint guideline of the American Cancer Society, the U.S. Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology (...) for CT colonography to be an effective screening test. Based on the above, CT colonography for the purpose of colon cancer screening meets the TEC criteria. Project page URL Indexing Status Subject indexing assigned by NLM MeSH Blue Cross Blue Shield Insurance Plans; Colonic Neoplasms /diagnosis /radiography; Colonic Polyps /diagnosis /radiography; Colonography, Computed Tomographic /methods; Colonoscopy; Device Approvals; Outcome Assessment (Health Care); Technology Assessment, Biomedical; United

2009 Health Technology Assessment (HTA) Database.

177. Fecal immunochemical tests for colorectal cancer screening: a systematic review of accuracy and compliance

Fecal immunochemical tests for colorectal cancer screening: a systematic review of accuracy and compliance Fecal immunochemical tests for colorectal cancer screening of average risk individuals: a systematic review of accuracy and compliance Fecal immunochemical tests for colorectal cancer screening of average risk individuals: a systematic review of accuracy and compliance Mujoomdar M, Cimon K, Spry C Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mujoomdar M, Cimon K, Spry C. Fecal immunochemical tests for colorectal cancer screening of average risk individuals: a systematic review of accuracy and compliance . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' objectives To review the evidence on diagnostic accuracy and patient compliance when using fecal immunochemical tests to screen for colorectal

2009 Health Technology Assessment (HTA) Database.

178. Fecal immunochemical tests for colorectal cancer screening: a systematic review of accuracy and compliance

to deciding if FIT is an appropriate CRC screening tool. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Colorectal Neoplasms; Early Detection of Cancers; Immunologic Tests; Mass Screening; Occult Blood; Predictive Value of Tests Language Published English Country of organisation Canada Province or state Ontario Address for correspondence Canadian Agency for Drugs and Technologies in Health, 865 Carling Avenue, Suite 600, K1S 5S8 Ottawa, Ontario Canada Email: htainfo@cadth.ca (...) Fecal immunochemical tests for colorectal cancer screening: a systematic review of accuracy and compliance Fecal immunochemical tests for colorectal cancer screening: a systematic review of accuracy and compliance Fecal immunochemical tests for colorectal cancer screening: a systematic review of accuracy and compliance Mujoomdar M, Cimon K, Spry C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality

2009 Health Technology Assessment (HTA) Database.

179. Fecal immunochemical testing in colorectal cancer screening of average risk individuals: economic evaluation

was associated with a cost per QALY of $4,350, which was robust to sensitivity analysis. If jurisdictions implement screening programs using FIT, volume-based contracts could be used to achieve lower prices for the FIT assays. To optimize FIT test performance, programs could include the testing of two to three stool samples. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Colorectal Neoplasms; Early Detection of Cancer; Fecess; Mass Screening; Occult Blood Language Published English (...) Fecal immunochemical testing in colorectal cancer screening of average risk individuals: economic evaluation Fecal immunochemical testing in colorectal cancer screening of average risk individuals: economic evaluation Fecal immunochemical testing in colorectal cancer screening of average risk individuals: economic evaluation Heitman S, Au F, Hilsden R, Manns B Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation

2009 Health Technology Assessment (HTA) Database.

180. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. Full Text available with Trip Pro

Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. To determine the risk of colorectal cancer after screening with flexible sigmoidoscopy.Randomised controlled trial.Population based screening in two areas in Norway-city of Oslo and Telemark county (urban and mixed urban and rural populations).55 736 men and women aged 55-64 years.Once only flexible sigmoidoscopy screening with or without a single round of faecal occult blood testing (n=13 (...) 823) compared with no screening (n=41 913).Planned end points were cumulative incidence and mortality of colorectal cancer after 5, 10, and 15 years. This first report from the study presents cumulative incidence after 7 years of follow-up and hazard ratio for mortality after 6 years.No difference was found in the 7 year cumulative incidence of colorectal cancer between the screening and control groups (134.5 v 131.9 cases per 100 000 person years). In intention to screen analysis, a trend towards

2009 BMJ Controlled trial quality: predicted high